Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration

Abstract Infliximab (IFX) has transformed the management of inflammatory bowel diseases (IBD). While intravenous (IV) IFX has been effective, a subcutaneous (SC) formulation offers advantages in convenience and cost. However, there is lack of evidence regarding the transition from IV to SC-IFX, espe...

Descripción completa

Detalles Bibliográficos

Autores principales:	Bokyeong Lee, Minjee Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2024-10-01
Colección:	Scientific Reports
Materias:	Infliximab Inflammatory bowel disease Subcutaneous administration Transition therapy Inadequate response
Acceso en línea:	https://doi.org/10.1038/s41598-024-75693-7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!